 The effectiveness of cryoprotection of onycholysis secondary to Docetaxel is not well established in this population breast cancer in the adjuvant setting and is based solely on a publication Scotté that does not contain the same therapeutic modalities dose significantly higher. The few studies available have heterogeneous populations, nonrandomized, retrospective or with a small sample. 